Department of Urology, University of Florida, 655 8th St W, Jacksonville, FL, 32209, USA.
Department of Biostatistics, University of Florida, Jacksonville, FL, USA.
Int Urol Nephrol. 2020 Jun;52(6):999-1008. doi: 10.1007/s11255-020-02408-y. Epub 2020 Feb 17.
Prostatic urethral lift (PUL), is a relatively new minimally invasive procedure for treatment of benign prostatic hyperplasia (BPH).This article is a systematic review and meta-analysis of all the articles published including follow-up of at least 24 months to analyze sustainability of results.
We performed a critical review in according to the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. From a total 768 published articles that matched our search terms, 5 studies with minimum follow-up of 24 months were selected for comparison and data analyzed in terms of baseline characteristics, functional, and sexual health outcomes.
Included in the analyses are five studies with a minimum follow-up of 24 months. A total of 386 patients underwent PUL and 322 patients (83.4%) are available for follow-up at 24 months. The randomized studies are grouped as group A and non-randomized studies as group B. At 24 months, the mean reduction in International Prostate Symptom Score (IPSS) from baseline was 9.1 in group A and 10.4 in group B. The mean improvement in peak flow rate (Q) was 3.7 mL/s in group A and 3 mL/s in group B, and quality of life (QoL) improved by 2.2 in both groups.
PUL is a well-tolerated, minimally invasive therapy for BPH that provides favorable and durable symptomatic, sexual health, and functional outcomes up to 24 months. Longer follow-up and randomized studies comparing to current standards are required to further confirm the long-term sustainability of PUL.
前列腺尿道提升术(PUL)是一种治疗良性前列腺增生(BPH)的相对较新的微创方法。本文是对所有已发表文章的系统评价和荟萃分析,包括至少 24 个月的随访,以分析结果的可持续性。
我们根据系统评价和荟萃分析的首选报告项目(PRISMA)指南进行了批判性评价。从总共匹配我们搜索条件的 768 篇已发表文章中,选择了 5 项最低随访 24 个月的研究进行比较,并根据基线特征、功能和性健康结果进行数据分析。
纳入分析的是 5 项最低随访 24 个月的研究。共有 386 例患者接受了 PUL 治疗,322 例(83.4%)可在 24 个月时进行随访。随机研究分为 A 组,非随机研究分为 B 组。24 个月时,A 组的国际前列腺症状评分(IPSS)从基线的平均下降为 9.1,B 组为 10.4。A 组的最大尿流率(Q)平均改善 3.7ml/s,B 组为 3ml/s,两组的生活质量(QoL)均改善 2.2。
PUL 是一种耐受良好的微创治疗 BPH 的方法,可提供有利且持久的症状、性健康和功能结果,最长可达 24 个月。需要进行更长时间的随访和随机研究,以与目前的标准进行比较,以进一步证实 PUL 的长期可持续性。